Willingness to pay for a hypothetical malaria vaccine in Brazil: a cross-sectional study and the implications

Costa, Maria José Labis da; Nascimento, Gesiane Cavalcante; Athie, Thannuse Silva; Silva, Juliana de Sales; Reis, Edna Afonso; Martin, Antony; Godman, Brian; Godói, Isabella Piassi Dias

doi:10.2217/cer-2021-0073

Cited by 6 publications

(2 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There have been many initiatives to increase research and development in the pharmaceutical industry for other urgent public health needs. Some authors have proposed government economic incentives to advance research and development into antibiotics for multi-resistant bacteria [ 45 , 46 ], cancer drugs [ 47 , 48 ], medicines [ 49 ], and malaria vaccines [ 50 ]. These incentives may include research grants, rewards for research advancements, and facilitating access to knowledge through open-source platforms [ 49 ].…”

Section: Discussionmentioning

confidence: 99%

How Did We Get Here: The Best Vaccines Ever Facing the Highest Public Hesitancy?

Ferreccio

2023

Vaccines

View full text Add to dashboard Cite

mRNA vaccine technology is the most interesting final product of decades of research. This new platform for public health is simple to transfer to low-income countries and can be used against diverse agents, including cancer. It is environmentally clean, relatively low-cost, and does not use animals for its production. Most importantly, mRNA vaccines have been highly efficacious in avoiding serious disease and death from COVID-19. Yet, at the highest point of the pandemic, many voices, including some from prominent positions, opposed their use. Similarly, the Human Papillomavirus (HPV) vaccines, which are highly effective, very safe, and probably confer long life protection against its HPV types, faced strong parents’ hesitancy. Vaccine hesitancy has been the subject of extensive research, focusing primarily on factors associated with the public, the political environment, and messaging strategies. However, the issue of unfair worldwide access to the COVID-19 vaccines has recently sparked significant debate about the vaccine industry’s role. Recent data demonstrated that the system’s perceived unfairness with the masses is behind the growing populist anti-vaccine movements worldwide. The association between populism and antivaccine attitudes has been reported at country and individual levels. The anti-science attitudes behind vaccine hesitancy emerge when the scientist is not found credible due to the suspicion that they had monetary investments in pharmaceutical companies. Here, I argue that the obscurity of the vaccine market, but also its unfairness, are important factors contributing to vaccine hesitancy. The purpose of this commentary is to stimulate a review of current market regulations and to improve its transparency and fairness, particularly in the context of public health emergencies. By doing so, a new pandemic would find us better prepared. The general population and much of the healthcare community often ignore the years of dedicated work and substantial public funding that enabled the discovery and design of vaccines. Conversely, pharmaceutical companies often over-emphasize their investments in research and development. A decade ago, Marcia Angell provided a detailed breakdown of pharmaceutical expenses, revealing that marketing and administration costs were 2.5 times higher than research and development expenses; recently, Olivier Wouters confirmed the high expenditures of the pharmaceutical industry in lobbying and political campaign contributions. In this commentary, I will present the cases of HPV and COVID-19 vaccines as examples of when vaccines, instead of being public health goods, became market goods, creating large inequities and health costs. This failure is a structural cause behind more ideological vaccine hesitancy, less studied so far.

show abstract

Section: Discussionmentioning

confidence: 99%

How Did We Get Here: The Best Vaccines Ever Facing the Highest Public Hesitancy?

Ferreccio

2023

Vaccines

View full text Add to dashboard Cite

show abstract

“…The WTP for a hypothetical vaccine has been examined in several recent studies, including vaccine for the COVID-19 in the U.S. [ 21 ], Japan [ 22 ] and Chile [ 23 ] prior to the launch of mRNA vaccines, as well as vaccine for malaria in Brazil [ 24 ].…”

Section: Introductionmentioning

confidence: 99%

Willingness to pay for an mRNA-based anti-cancer treatment: results from a contingent valuation study in Israel

Ben-Aharon,

Sergienko,

Iskrov

et al. 2024

Isr J Health Policy Res

View full text Add to dashboard Cite

Background mRNA technology is currently being investigated for a range of oncology indications. We assessed the willingness to pay (WTP) of the general population in Israel for a hypothetical novel mRNA-based treatment for oncology indications. Methods We used a contingent valuation methodology to elicit WTP using a web-based questionnaire. A sample of adult participants were presented with a hypothetical scenario in which an mRNA-based intervention increased the likelihood of a cure for various cancer types from 20% to 40% (half of the sample), or 60% (the other half of the sample). Results 531 respondents completed the questionnaire. The mean, median and mode WTP for the proposed hypothetical treatment in both scenarios were ILS65,000 (± ILS114,000), ILS20,000 and ILS50,000, respectively (1USD = 3.4ILS). The WTP was skewed towards zero, and 9.6% of the respondents were not willing to pay any amount. WTP higher amounts was significantly associated with higher income (p < 0.01), self-reported good health (p < 0.05), supplementary health insurance (p < 0.05), Jews compared to other populations (p < 0.01), interest in technology (p < 0.001) and a tendency to adopt medical innovations (p < 0.001). No statistical difference between the 40% vs. the 60% potential cure scenarios was found. Logistic and OLS regressions indicated that age, religion, income, and interest in adopting medical innovations were the best predictors of respondents' WTP. Conclusion Despite the scientific breakthroughs in oncology treatment over the last few decades, many types of cancer are still incurable. Given the expected development of innovative mRNA-based treatments for cancer, these results should inform policymakers, the pharmaceutical industry and other stakeholders on the future coverage and reimbursement of these technologies incorporating patients’ and societal views. To date, WTP considerations have not been given much weight in prioritization of drug reimbursement processes, neither in Israel nor in other countries. As a pioneer in adoption of the mRNA technology, Israel can also lead the incorporation of WTP considerations in this field.

show abstract

Acceptance of malaria vaccine among mothers of under-five children in Nigeria: Results from the M-VAN survey

Musa,

Sulaiman,

Isma'il Tsiga-Ahmed

et al. 2024

Vacunas

View full text Add to dashboard Cite

Willingness to pay for a hypothetical malaria vaccine in Brazil: a cross-sectional study and the implications

Cited by 6 publications

References 36 publications

How Did We Get Here: The Best Vaccines Ever Facing the Highest Public Hesitancy?

How Did We Get Here: The Best Vaccines Ever Facing the Highest Public Hesitancy?

Willingness to pay for an mRNA-based anti-cancer treatment: results from a contingent valuation study in Israel

Acceptance of malaria vaccine among mothers of under-five children in Nigeria: Results from the M-VAN survey

Contact Info

Product

Resources

About